Free Trial

Cingulate Q3 2023 Earnings Report

Cingulate logo
$4.32 +0.10 (+2.25%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cingulate EPS Results

Actual EPS
-$6.00
Consensus EPS
-$4.80
Beat/Miss
Missed by -$1.20
One Year Ago EPS
N/A

Cingulate Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cingulate Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Cingulate Earnings Headlines

Ex-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”
Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. Should you sit on the sideline while this is happening?
Cingulate price target adjusted to $20 from $8 at H.C. Wainwright
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING), a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

View Cingulate Profile

More Earnings Resources from MarketBeat